سعر فارموروبيسين ار دي 50 مجم فيال 2022

Epirubicin 50 mg rapid-dissolution (RD) powder vial for intravenous use (Pfizer), single vial.

• Component of adjuvant therapy in patients with evidence of axillary node tumour involvement following resection of primary breast cancer.Population: AdultsDailyMed (U.S. NLM)

• Most common (>=10%): leukopenia, neutropenia, anaemia, thrombocytopenia, amenorrhoea, lethargy, nausea/vomiting, mucositis, diarrhoea, infection, conjunctivitis/keratitis, alopecia, local skin toxicity and rash/itch.International label, equivalent formulation · DailyMed (U.S. NLM)

• Contraindicated in severe myocardial insufficiency, recent myocardial infarction or severe arrhythmias, previous treatment with maximum cumulative anthracycline doses, severe persistent drug-induced myelosuppression, severe hepatic impairment, and severe hypersensitivity to epirubicin, other anthracyclines or anthracenediones.International label, equivalent formulation · DailyMed (U.S. NLM)

• Boxed warning: cardiac toxicity (cardiomyopathy risk proportional to cumulative dose: 0.9% at 550 mg/m2, 1.6% at 700 mg/m2, 3.3% at 900 mg/m2), secondary malignancies, extravasation and tissue necrosis, and severe myelosuppression.International label, equivalent formulation · DailyMed (U.S. NLM)

• Can cause fetal harm; avoid use during the first trimester. Reports of fetal and/or neonatal cardiotoxicity after in-utero exposure.International label, equivalent formulation · DailyMed (U.S. NLM)
• Advise not to breastfeed during treatment and for at least 7 days after the last dose.International label, equivalent formulation · DailyMed (U.S. NLM)

• Epirubicin: Anthracycline topoisomerase inhibitor (US Ellence label).